The Ultimate Guide To Vagus Nerve Stimulation

When it comes to healing and restoring balance in the body, few nerves are as essential — or as often overlooked — as the vagus nerve. Acting as a communication superhighway between the brain and key vital organs, it plays a central role in regulating digestion, heart rate, mood, inflammation, and the body’s response to stress.

In recent years, research has shown that gentle stimulation of the vagus nerve may help support individuals dealing with symptoms associated with anxiety, depression, IBS, chronic pain, sleep issues, and other conditions linked to autonomic nervous system imbalance. As interest in non-invasive vagus nerve stimulation continues to grow, clinicians and at-home users are looking for safe, practical, and evidence-informed ways to better understand how this therapy works.

In this guide, we’ll explain what vagus nerve stimulation is, how implanted VNS differs from non-invasive options like tVNS and taVNS, and why the ear is commonly used in non-invasive protocols. We’ll also explore three modalities being discussed in the space — TENS-style electrical stimulation, microcurrent therapy, and therapeutic ultrasound — while comparing what the research currently supports, what remains promising, and what should still be considered experimental.

You’ll also learn about common research parameters, important safety precautions, questions clinicians should ask before recommending at-home VNS, and the types of electrotherapy products and accessories commonly used in VNS-related protocols.

Our goal is to give clinicians, patients, and wellness-minded users a clear, honest, and practical starting point for understanding the evolving role of vagus nerve stimulation in modern pain relief, recovery, and nervous system support.

What Is Vagus Nerve Stimulation?

The vagus nerve is the body’s longest cranial nerve. Its name comes from the Latin word for “wandering,” which accurately describes its path through the body. Beginning in the brainstem, the vagus nerve travels through the neck and chest and reaches key organs including the heart, lungs, stomach, and intestines. Because of this broad connection, it plays an important role in communication between the brain and many of the body’s major internal systems.

As a major pathway of the parasympathetic nervous system, the vagus nerve helps regulate functions often associated with the body’s “rest and digest” state. These include heart rate, breathing, digestion, immune signaling, inflammation, and communication between the brain and gut. Researchers have also identified the vagus nerve as an important part of the body’s inflammatory reflex, a neural pathway that helps the nervous system detect and regulate inflammatory activity. Borovikova et al. (2000) described a parasympathetic anti-inflammatory pathway through which the brain can help modulate systemic inflammatory responses.

Vagus nerve stimulation, or VNS, refers to the use of targeted stimulation intended to activate or influence vagus nerve signaling. In simple terms, the goal is to help support communication between the brain, nervous system, immune system, and internal organs. Because the vagus nerve is involved in so many regulatory processes, researchers have studied VNS for a wide range of health concerns, including inflammation, mood, pain, sleep, digestion, and autonomic nervous system imbalance.

One of the reasons VNS has gained attention is its potential role in helping regulate inflammation and immune activity. In a human study involving patients with rheumatoid arthritis, Koopman et al. (2016) found that vagus nerve stimulation targeting the inflammatory reflex modulated TNF production and reduced inflammation, supporting the idea that neuromodulation can influence immune signaling in humans.

When vagal tone or autonomic regulation is disrupted, individuals may experience symptoms related to stress response, digestion, sleep, mood, pain sensitivity, fatigue, and inflammation. However, VNS should not be presented as a cure-all. The strength of the evidence varies depending on the condition being studied, the method of stimulation, the device used, and the treatment protocol. For this reason, VNS is best understood as an evolving area of neuromodulation research rather than a single universal treatment.

In the sections below, we’ll look more closely at how VNS is delivered, including the difference between implanted and non-invasive approaches, what tVNS and taVNS mean, why the ear is commonly used in non-invasive protocols, and how modalities such as TENS-style stimulation, microcurrent therapy, and therapeutic ultrasound fit into the broader conversation.

Implanted VNS vs Non-Invasive VNS

Vagus nerve stimulation can generally be divided into two categories: implanted VNS and non-invasive VNS. Both are designed to influence vagus nerve signaling, but they differ in how stimulation is delivered, who typically uses them, and how established the clinical evidence is.

Implanted vagus nerve stimulation is the more established medical approach. It involves surgically placing a small pulse generator under the skin, usually in the chest, with a lead wire connected to the vagus nerve in the neck. The device delivers mild electrical impulses to the vagus nerve and is typically used under physician supervision for specific medical conditions. Mayo Clinic describes implanted VNS as an FDA-approved treatment option for epilepsy and depression, while Cleveland Clinic notes that VNS has also been approved as a rehabilitation aid for certain stroke patients (Mayo Clinic, 2024; Cleveland Clinic, 2022). A review by Afra et al. (2021) also describes VNS therapy as an FDA-approved device therapy for drug-resistant epilepsy.

Non-invasive vagus nerve stimulation is designed to influence vagal pathways from outside the body, without surgery or implanted hardware. Instead of placing a device around the vagus nerve, non-invasive methods use external stimulation applied through the skin.

The appeal of non-invasive VNS is that it may offer a more accessible and lower-risk way to explore vagus nerve modulation compared with implanted devices. However, non-invasive VNS should not be treated as identical to implanted VNS. Yap et al. (2020) emphasized that the field still needs more standardization around stimulation sites, device types, treatment parameters, and clinical protocols.

Simply put, implanted VNS is a clinically established, physician-managed therapy for specific medical conditions, while non-invasive VNS is an emerging area of neuromodulation research that uses external stimulation to influence vagal pathways without surgery. This distinction is important before exploring terms like tVNS and taVNS, which describe some of the most commonly studied forms of non-invasive electrical vagus nerve stimulation.

What is tVNS/taVNS?

tVNS stands for transcutaneous vagus nerve stimulation. The word “transcutaneous” means “through the skin,” so tVNS refers to non-invasive stimulation intended to influence vagus nerve pathways from outside the body. Instead of using a surgically implanted device, tVNS uses external stimulation applied to selected areas of the skin.

taVNS stands for transcutaneous auricular vagus nerve stimulation. This is a more specific form of tVNS that applies stimulation to areas of the outer ear associated with the auricular branch of the vagus nerve. This is why taVNS is often discussed in connection with ear-clip electrodes or other ear-based stimulation methods. Wang et al. (2020) describe taVNS as a method that applies electrical current to the cutaneous receptive field of the auricular branch of the vagus nerve.

Research interest in tVNS and taVNS has grown because these approaches may offer a more accessible way to study vagus nerve modulation compared with implanted VNS. However, the field is still evolving. Farmer et al. (2021) emphasized that tVNS research should report key details such as stimulation location, frequency, pulse width, current intensity, session duration, electrode type, and device characteristics. This matters because results can vary depending on how, where, and for how long stimulation is applied.

For clinicians and end users, the most important takeaway is that tVNS and taVNS are not simply general “nerve stimulation” techniques. While research is promising, tVNS and taVNS should be understood as developing clinical and wellness tools rather than one-size-fits-all treatments.

Why the Ear Is Commonly Used for Non-Invasive VNS

The ear is commonly used in non-invasive vagus nerve stimulation because it provides one of the few accessible surface pathways to vagus nerve signaling. While most of the vagus nerve travels deep through the neck, chest, and abdomen, a smaller branch called the auricular branch of the vagus nerve, or ABVN, reaches parts of the external ear. This branch is sometimes referred to as Arnold’s nerve and provides sensory innervation to specific regions of the outer ear (Butt et al., 2020).

This is why many non-invasive VNS protocols focus on ear-based stimulation rather than trying to stimulate the main vagus nerve directly in the neck. In taVNS, external stimulation is applied to selected areas of the ear. Common research targets include the cymba conchae, cavum conchae, and tragus, although researchers continue to study which locations may provide the most reliable vagal engagement.

Figure 1: Common taVNS target areas of the outer ear, including the cymba conchae, cavum conchae, and tragus, along with the auricular branch of the vagus nerve pathway.

Image Source : (Peuker and Filler, 2002)

The cymba conchae has received significant attention in research because it is believed to have strong auricular vagus nerve involvement. In a human fMRI study, Frangos et al. (2015) found that mild electrical stimulation of the cymba conchae activated the nucleus tractus solitarius, or NTS, which is considered the first central relay for vagal signals in the brainstem. This finding is important because it provides human evidence that stimulation of a specific region of the outer ear may influence central vagal pathways.

However, the anatomy of the ear is complex, and not every area of the ear is innervated by the vagus nerve in the same way. Some regions are supplied by other nerves, including branches of the trigeminal, facial, and glossopharyngeal nerves. Butt et al. (2020) emphasized that the anatomical basis for taVNS depends on understanding where the auricular branch of the vagus nerve is most likely to be represented. This is one reason proper electrode placement matters in research and clinical protocols.

This makes ear-based VNS more accessible than implanted VNS and easier to study across different patient populations. At the same time, stimulation location, intensity, pulse width, frequency, treatment duration, and device type can all influence outcomes, which is why consensus recommendations encourage researchers to report these details clearly in tVNS studies (Farmer et al., 2021). Because taVNS depends on reaching specific ear regions externally, the next question is which type of stimulation is most commonly studied for this purpose.

Modality 1 : TENS-Style Electrical Stimulation

TENS-style electrical stimulation is one of the most relevant modalities in the non-invasive VNS space because much of the current taVNS research uses controlled electrical stimulation delivered through external electrodes. While traditional TENS is commonly used for pain relief by stimulating peripheral nerves through the skin, taVNS applies a similar surface-stimulation concept with a more specific goal: influencing vagus nerve pathways through targeted placement and measurable stimulation settings.

One of the key strengths of TENS-style stimulation is adjustability. Clinicians and researchers can control variables such as frequency, pulse width, intensity, duty cycle, treatment time, and electrode type. These details matter because taVNS is not simply “regular TENS on the ear.” It is a targeted neuromodulation approach where stimulation location and parameters can influence results. Farmer et al. (2021) emphasized that tVNS studies should clearly report stimulation site, frequency, pulse width, current intensity, duty cycle, session duration, electrode type, and device characteristics so protocols can be better understood and compared.

Research has explored taVNS for several outcomes relevant to pain management and nervous system regulation, including chronic pain, sleep, mood, autonomic activity, and inflammation. For pain specifically, Costa et al. (2024) concluded that tVNS shows promise for reducing pain intensity in chronic pain conditions, while Duff et al. (2024) reviewed auricular vagus nerve stimulation as a growing non-drug neuromodulation option for acute and chronic pain.

It is important, however, to explain that there is no single universal taVNS protocol. Published studies vary in stimulation location, frequency, pulse width, intensity, session length, and treatment schedule. Yap et al. (2020) noted that this lack of standardization remains one of the major challenges in translating tVNS research into everyday clinical practice. For example, Badran et al. (2018) studied short trains of taVNS using different pulse widths and frequencies, including pulse widths of 100, 200, and 500 microseconds and frequencies of 1, 10, and 25 Hz, while measuring effects on heart rate. These settings are useful as research examples, but they should not be presented as a one-size-fits-all recommendation.

From a practical standpoint, TENS-style taVNS protocols may involve a compatible stimulator, ear clip electrodes or specialized auricular electrodes, lead wires, conductive gel/spray if needed, and careful intensity adjustment. Stimulation in research settings is generally described as mild or tolerable rather than painful. Safety should still be taken seriously. Kim et al. (2022) reported that taVNS is generally associated with mild and transient adverse effects in clinical studies, but also emphasized the need for continued safety evaluation because many human studies remain relatively small.

Overall, TENS-style electrical stimulation currently has the strongest direct research connection to non-invasive VNS when discussed in the context of taVNS. It is adjustable, familiar to many clinicians, and supported by a growing body of research. However, outcomes depend on the stimulation site, device compatibility, treatment parameters, patient selection, and clinical goals. For this reason, TENS-style taVNS should be presented as a promising, research-supported neuromodulation approach — not a guaranteed cure.

Modality 2 : Microcurrent Therapy

Microcurrent therapy is another electrotherapy modality being discussed in the broader conversation around nervous system regulation and non-invasive neuromodulation. Unlike traditional TENS, which typically uses stronger sensory-level stimulation, microcurrent therapy uses very low-amplitude electrical current, often below the level of strong sensation. A 2022 review described microcurrent as a non-invasive electrotherapy that applies sub-sensory electrical currents, generally less than 1 milliamp, which are intended to interact with the body’s natural bioelectrical processes (Kolimechkov et al., 2022).

In the context of vagus nerve stimulation, microcurrent should be presented carefully. A more accurate way to explain it is that microcurrent may be of interest because it offers a gentle, low-level form of electrical stimulation that some clinicians explore for pain, recovery, and nervous system support. A systematic review by Iijima and Takahashi (2021) found that microcurrent therapy significantly improved shoulder and knee pain compared with sham treatment in selected studies, without severe adverse events, although the authors also noted that more research is needed for broader applications.

This makes microcurrent relevant to a VNS-focused article, but in a more indirect way than TENS-style taVNS. Microcurrent has research support in areas such as musculoskeletal pain and tissue healing, while taVNS has more direct evidence for vagus nerve modulation. For example, a 2022 meta-analysis on external microcurrent devices for wound healing reported that microcurrents were effective and safe for improving wound area, healing time, and pain compared with standard wound care alone (Avendaño-Coy et al., 2022).

From a practical standpoint, the appeal of microcurrent is comfort and tolerability. Because the current is very low, many users may find it gentler than traditional TENS-style stimulation. This may make microcurrent attractive for sensitive users or clinician-guided protocols where comfort is a priority. However, comfort does not automatically mean the treatment is vagus-specific. To make a VNS-related claim, the stimulation method, placement, output, and research basis all matter.

The most responsible takeaway is that microcurrent therapy is a promising low-level electrotherapy modality, but the current evidence does not support presenting it as strongly as taVNS for vagus nerve stimulation. In this guide, microcurrent is best described as an emerging or supportive modality within the broader neuromodulation conversation. It may have value for pain management, tissue recovery, and gentle electrical stimulation, but more direct research is needed before it can be considered a well-established VNS method.

Modality 3 : Therapeutic Ultrasound

Therapeutic ultrasound is one of the most interesting emerging modalities in the non-invasive VNS conversation, especially because it uses sound-wave energy rather than electrical current. Unlike TENS-style stimulation or microcurrent therapy, ultrasound delivers mechanical acoustic energy into tissue. This makes it a different type of neuromodulation tool, with a developing research base that should be presented as promising but still investigational.

How Ultrasound Differs from Electrical Stimulation

TENS-style stimulation and microcurrent therapy rely on electrical current delivered through the skin. Therapeutic ultrasound works differently by using acoustic energy that travels through tissue. Depending on the device, frequency, intensity, duty cycle, treatment head design, and application technique, ultrasound may interact with soft tissue and nerve tissue through mechanical, thermal, and cellular effects.

This difference is why ultrasound is attracting attention in neuromodulation research. Electrical taVNS depends heavily on electrode placement, skin conductivity, and current flow, while ultrasound may offer another way to influence tissue and nerve activity without direct electrical stimulation. However, ultrasound-based VNS should not be treated as the same thing as electrical taVNS. It is a separate, emerging area of research.

What the Research Is Exploring

In the context of vagus nerve stimulation, ultrasound research is still early. A 2024 review by Goyal et al. described non-invasive ultrasound stimulation of the vagus nerve as a novel and promising approach, but also emphasized that more clinical research is needed before firm conclusions can be made.

Research is also beginning to explore low-intensity focused ultrasound, or LIFU, for vagus nerve-related neuromodulation. A 2025 clinical study by Kohler et al. described ultrasound neuromodulation of the auricular branch of the vagus nerve as an emerging treatment approach for anxiety-related symptoms. In that study, participants used daily low-intensity focused ultrasound stimulation for four weeks, and researchers evaluated outcomes related to anxiety, depression, PTSD symptoms, and sleep.

Another 2025 study by Labree et al. described auricular ultrasonic vagus nerve stimulation using a device designed to deliver low-intensity focused ultrasound to the auricular branch of the vagus nerve through the skin. These studies support the concept that ultrasound may be able to influence vagal pathways, but they should still be viewed as early-stage evidence.

What This Means for Portable Ultrasound Units

Much of the strongest ultrasound-VNS research involves focused ultrasound systems or specialized research devices, not necessarily standard portable therapeutic ultrasound units. This means the results from focused ultrasound studies should not automatically be applied to every therapeutic ultrasound device, setting, or placement method.

Devices such as the US Pro 2000 2nd Edition Portable Ultrasound Unit are commonly discussed in clinician and wellness communities for vagus nerve support, and there is growing interest in how portable ultrasound may fit into the broader ultrasound neuromodulation conversation. The Institute of Noetic Sciences announced an exploratory pilot study designed to evaluate whether the US Pro 2000 2nd Edition Portable Ultrasound Unit may help improve memory and cognitive function in individuals with memory difficulties. That is relevant because it shows the unit is being explored in a formal research setting. However, it should be described as early-stage exploratory research, not proof that the device is clinically validated for VNS.

Some practitioners report using portable therapeutic ultrasound on low settings near areas associated with vagus nerve pathways, such as around the head, neck, or skull-adjacent tissues. The theory is that low-intensity ultrasound may influence nearby soft tissue, nerve tissue, or autonomic signaling pathways. However, at this time, peer-reviewed evidence does not clearly establish that a standard portable therapeutic ultrasound unit on a “low” setting reliably stimulates the vagus nerve in the same way as studied electrical taVNS or specialized focused ultrasound systems. Portable therapeutic ultrasound is being explored by some clinicians and researchers as part of the broader ultrasound neuromodulation conversation, but it should still be considered an emerging and investigational approach for VNS-related use.

Safety Considerations

Safety is especially important when discussing ultrasound near the head, neck, skull, throat, ear, carotid artery, or other sensitive nerve and vascular structures. Readers should not assume that any ultrasound device can be safely used near these areas without professional guidance.

Until more standardized research exists, ultrasound-based VNS should be approached as a clinician-guided and investigational modality. Users should follow device instructions, avoid unsupported placements, and consult a qualified healthcare professional before using ultrasound for nervous system or vagus nerve-related goals.

Overall, therapeutic ultrasound may become an important part of the future of non-invasive vagus nerve stimulation. Early research suggests that ultrasound-based neuromodulation may influence vagal pathways and may have potential applications for anxiety, mood, sleep, cognition, and autonomic regulation. However, compared with TENS-style taVNS, the clinical evidence is still younger and less standardized. For that reason, therapeutic ultrasound should be described as a promising emerging modality with exciting research underway, but not yet a fully established or one-size-fits-all VNS treatment.

Evidence Comparison: What Is Proven, Promising, and Experimental

Not all vagus nerve stimulation methods have the same level of research support. Some approaches, such as implanted VNS and electrical taVNS, have a stronger clinical foundation, while others, such as microcurrent and therapeutic ultrasound for VNS, are still developing. The goal is not to rank one modality as “best,” but to understand where the evidence currently stands.

In simple terms, implanted VNS is the most clinically established, while TENS-style taVNS has the strongest non-invasive research support. Microcurrent and therapeutic ultrasound are both interesting and potentially valuable, but they should be described more cautiously. Microcurrent is best presented as a supportive low-level electrotherapy option, while ultrasound should be presented as an emerging neuromodulation modality with exciting research still underway.

For clinicians and end users, the safest approach is to match the modality to the evidence, the intended use, the device, and the individual’s health needs.

Common Research Parameters

Research settings vary depending on the study goal, stimulation site, device type, patient population, and outcome being measured. However, published taVNS studies do give clinicians and patients a useful starting point for the types of settings and questions to discuss with a qualified healthcare provider.

In research, common taVNS parameters usually include the stimulation site, waveform, frequency, pulse width, intensity, duty cycle, session duration, electrode type, and treatment schedule. Farmer et al. (2021) specifically recommended that tVNS studies report these technical details so protocols can be compared more accurately across studies. Yap et al. (2020) also noted that differences in stimulation sites, devices, and parameters remain one of the major challenges in translating tVNS research into everyday clinical practice.

A broad research-informed starting discussion may include:

Waveform is another important topic to discuss. Monophasic stimulationdelivers current in one direction, while biphasic stimulation alternates current direction. In many electrotherapy and neuromodulation applications, biphasic or charge-balanced stimulation is often preferred because it can reduce net charge buildup at the electrode-tissue interface. This may improve comfort and help reduce the risk of irritation or overstimulation for some users, although it does not mean biphasic stimulation is automatically better for every VNS protocol. Research is still comparing how different waveform designs affect comfort, tolerability, and physiological response.

For patients and end users, the most important takeaway is that parameters should be individualized. A helpful doctor or clinician conversation may sound like: “I read that taVNS studies commonly report frequency, pulse width, intensity, waveform, duty cycle, electrode type, and session duration. Based on my health history, medications, and treatment goals, what would be a safe starting point to consider?” That kind of question keeps the conversation evidence-informed while avoiding unsafe self-prescribing.

For clinicians, the goal is not to copy one study exactly, but to understand how each parameter may affect comfort, safety, and potential outcomes. Starting low, monitoring patient response, and adjusting carefully is generally more responsible than assuming stronger stimulation is better. In taVNS, stimulation is commonly described as mild, tolerable, or sensory-level — not painful.

Safety, Contraindications, and When Not to Use VNS

Vagus nerve stimulation should be approached thoughtfully, especially when using electrical stimulation, microcurrent, or ultrasound near the ear, head, neck, or chest. While non-invasive VNS methods are often described as low-risk in research settings, they are still forms of neuromodulation and may not be appropriate for everyone.

For taVNS specifically, safety reviews generally report that side effects are usually mild and temporary, such as skin irritation, tingling, warmth, discomfort, headache, dizziness, or ear discomfort. However, Kim et al. (2022) noted that taVNS safety research is still developing and that more consistent reporting of adverse events is needed across studies.

VNS may not be appropriate for individuals who arepregnant, have heart rhythm problems, significant heart disease, breathing disorders such as asthma, COPD, or sleep apnea, active ulcers, dysautonomia, insulin-dependent diabetes, or only one functioning vagus nerve. Cleveland Clinic also lists pregnancy, breathing problems, active peptic ulcer disease, insulin-dependent diabetes, dysautonomias, heart arrhythmias, and other forms of brain stimulation as situations where a person may not be a candidate for VNS.

Extra caution is also important for anyone with implanted electronic devices, such as a pacemaker, defibrillator, cochlear implant, implanted stimulator, or other active medical device. Electrical stimulation may interfere with implanted electronics, and ultrasound near implanted hardware or sensitive anatomy should only be considered under medical guidance.

Do not place electrodes across the chest, over the front of the neck, over the carotid sinus, over broken or irritated skin, or near areas with reduced sensation unless directed by a qualified healthcare professional. Users should also avoid increasing intensity to a painful level. In taVNS research, stimulation is typically described as mild, tolerable, or sensory-level, not painful.

Therapeutic ultrasound requires its own safety considerations. Ultrasound should not be casually applied near the skull, eyes, throat, carotid artery, or sensitive nerve and vascular structures without professional guidance. Ultrasound-based VNS is still emerging, and research involving focused ultrasound systems should not automatically be applied to every portable ultrasound device or at-home protocol.

Stop treatment and speak with a healthcare professional if stimulation causes chest pain, fainting, shortness of breath, heart palpitations, severe dizziness, worsening headache, unusual neurological symptoms, skin burns, persistent irritation, or symptoms that feel concerning or unusual.

The safest approach is simple: VNS-related therapies should be discussed with a qualified clinician, especially for anyone with a diagnosed medical condition, implanted device, pregnancy, seizure history, heart condition, breathing disorder, or complex medication history. Non-invasive does not always mean risk-free.

Questions Clinicians Should Ask Before Recommending At-Home VNS

Before recommending at-home vagus nerve stimulation, clinicians should first determine whether the patient is an appropriate candidate. Non-invasive VNS may be well tolerated in many research settings, but it still involves neuromodulation and should be matched to the person’s health history, treatment goals, and risk factors. Safety reviews of taVNS generally describe it as feasible and well tolerated, but continued safety monitoring and consistent adverse-event reporting remain important (Kim et al., 2022; Farmer et al., 2021).

For clinicians, the goal is to make at-home VNS structured and safe rather than casual or experimental without oversight. A patient should leave the conversation knowing why they are using VNS, where stimulation should be applied, what device and settings are appropriate, how often to use it, and what warning signs mean they should stop.

At-home VNS should begin with a clinician-guided plan, not guesswork. The best approach is to start with clear goals, screen for risk factors, choose the appropriate modality, use conservative starting parameters, monitor patient response, and adjust only when appropriate.

Products and Accessories Used in Electrotherapy-Based VNS

Electrotherapy-based VNS protocols often require more than just a stimulation device. The setup may include ear clip electrodes, lead wires, conductive gel/spray, replacement accessories, and clear clinician guidance on placement and settings. Because VNS-related stimulation depends on device output, waveform, electrode placement, intensity, and patient tolerance, product selection should be based on the intended use and reviewed with a qualified healthcare professional.

For TENS-style taVNS, common accessories may include ear clip electrodes, lead wires, and a compatible portable TENS unit. TENSpros carries black ear clip electrodes commonly used for cranial electrotherapy stimulation, which may also be discussed in clinician-guided ear-based electrotherapy protocols. When reviewing any ear clip setup, clinicians should confirm device compatibility, lead wire connection, electrode contact quality, and whether conductive gel/spray is needed for comfort and signal consistency.

Waveform is another important consideration. The InTENSity 12 Digital TENS Unit operates with a symmetrical bi-phase rectangular wave, which may be helpful in electrotherapy discussions because biphasic or charge-balanced stimulation can reduce net charge buildup at the electrode-skin interface and may improve comfort for some users. The InTENSity Twin Stim III TENS & EMS Combination Unit uses a mono-phasic square pulse, which may also be used in certain electrotherapy applications but should be evaluated based on the intended protocol, patient tolerance, and clinician guidance.

For readers exploring microcurrent therapy, TENSpros also carries the InTENSity Select Combo TENS, EMS, IF & Microcurrent Combination Unit, which includes microcurrent as one of its available therapy modes. While the unit has fixed programs that are not directly linked to validated VNS protocols, reviewing the available settings may help clinicians and informed users better understand how microcurrent differs from traditional TENS-style stimulation. As discussed earlier, microcurrent should not be presented as a proven stand-alone VNS treatment, but it may be relevant as a gentle, low-level electrotherapy option within the broader neuromodulation conversation.

For therapeutic ultrasound, TENSpros carries portable ultrasound devices such as the US Pro 2000 2nd Edition Portable Ultrasound Unit and US 1000 3rd Edition Portable Ultrasound Unit. These devices are commonly used in therapeutic ultrasound applications and are being discussed by some clinicians in the broader conversation around ultrasound-based neuromodulation. Some practitioners have shown interest in low-setting ultrasound applications near tissues associated with vagus nerve pathways. However, ultrasound-based VNS is still emerging, and current research often involves focused ultrasound systems or specialized research devices. For that reason, results should not automatically be applied to every portable ultrasound unit, setting, or at-home protocol.

As interest in non-invasive vagus nerve stimulation continues to grow, the most important takeaway is that products and accessories should be viewed as tools — not one-size-fits-all treatments. The right setup depends on the modality being used, the patient’s health history, the intended goal, the device waveform, electrode placement, and clinician guidance. Whether someone is exploring TENS-style taVNS, microcurrent therapy, or therapeutic ultrasound, the best approach is to stay evidence-informed, start conservatively, prioritize safety, and ask the right questions before beginning at-home use.

FAQ Section with Schema

References

Afra, P., Adamolekun, B., Aydemir, N., & Watson, R. (2021). Evolution of the vagus nerve stimulation therapy system technology for drug-resistant epilepsy. Frontiers in Medical Technology, 3, 696543.

Avendaño-Coy, J., Gómez-Soriano, J., Goicoechea-García, C., Basco-López, J. A., & Taylor, J. (2022). Electrical microcurrent stimulation therapy for wound healing: A meta-analysis of randomized clinical trials. Journal of Tissue Viability, 31(2), 268–277.

Badran, B. W., Dowdle, L. T., Mithoefer, O. J., LaBate, N. T., Coatsworth, J., Brown, J. C., DeVries, W. H., Austelle, C. W., McTeague, L. M., & George, M. S. (2018). Neurophysiologic effects of transcutaneous auricular vagus nerve stimulation via electrical stimulation of the tragus: A concurrent taVNS/fMRI study and review. Brain Stimulation, 11(3), 492–500.

Borovikova, L. V., Ivanova, S., Zhang, M., Yang, H., Botchkina, G. I., Watkins, L. R., Wang, H., Abumrad, N., Eaton, J. W., & Tracey, K. J. (2000). Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature, 405(6785), 458–462.

Butt, M. F., Albusoda, A., Farmer, A. D., & Aziz, Q. (2020). The anatomical basis for transcutaneous auricular vagus nerve stimulation. Journal of Anatomy, 236(4), 588–611.

Cleveland Clinic. (2022). Vagus nerve stimulation: What it is, uses & side effects. Cleveland Clinic.

Costa, V., Nóbrega, A. C. L., & Teixeira, A. L. (2024). Transcutaneous vagus nerve stimulation effects on chronic pain: A systematic review and meta-analysis. Pain Reports, 9(5), e1160.

Duff, I. T., Lerman, I., & Sheth, S. A. (2024). Clinical efficacy of auricular vagus nerve stimulation in treating acute and chronic pain: A systematic review and meta-analysis. Pain and Therapy, 13, 1417–1439.

Farmer, A. D., Strzelczyk, A., Finisguerra, A., Gourine, A. V., Gharabaghi, A., Hasan, A., Burger, A. M., Jaramillo, A. M., Mertens, A., Majid, A., Verkuil, B., Badran, B. W., Ventura-Bort, C., Gaul, C., Beste, C., Warren, C. M., Quintana, D. S., Hämmerer, D., Freri, E., Frangos, E., … Koenig, J. (2021). International consensus based review and recommendations for minimum reporting standards in research on transcutaneous vagus nerve stimulation. Frontiers in Human Neuroscience, 14, 568051.

Frangos, E., Ellrich, J., & Komisaruk, B. R. (2015). Non-invasive access to the vagus nerve central projections via electrical stimulation of the external ear: fMRI evidence in humans. Brain Stimulation, 8(3), 624–636.

Goyal, M., Hamblin, M. R., & Tousif, K. (2024). Ultrasound stimulation of the vagus nerve as a treatment for anxiety and depression: A proof-of-concept review. Frontiers in Psychiatry, 15, 1376140.

Iijima, H., & Takahashi, M. (2021). Microcurrent therapy as a therapeutic modality for musculoskeletal pain: A systematic review accelerating the translation from clinical trials to patient care. Archives of Rehabilitation Research and Clinical Translation, 3(3), 100145.

Institute of Noetic Sciences. (2025). New study underway to improve memory & cognitive function.

Juan, E. J., González, R., Albors, G., Ward, M. P., & Irazoqui, P. (2014). Vagus nerve modulation using focused pulsed ultrasound. PLoS ONE, 9(11), e111896.

Kim, A. Y., Jang, E. H., Lee, S. W., & Lee, S. H. (2022). Safety of transcutaneous auricular vagus nerve stimulation: A systematic review and meta-analysis. Scientific Reports, 12, 22055.

Kohler, I., et al. (2025). Reduction of anxiety-related symptoms using low-intensity focused ultrasound neuromodulation of the auricular branch of the vagus nerve. JMIR Neurotechnology, 4, e69770.

Kolimechkov, S., Petkov, P., Alexandrova, A., & Dimitrova, D. (2022). Physiological effects of microcurrent and its application for maximising acute responses and chronic adaptations to exercise. European Journal of Applied Physiology, 123, 451–465.

Koopman, F. A., Chavan, S. S., Miljko, S., Grazio, S., Sokolovic, S., Schuurman, P. R., Mehta, A. D., Levine, Y. A., Faltys, M., Zitnik, R., Tracey, K. J., & Tak, P. P. (2016). Vagus nerve stimulation inhibits cytokine production and attenuates disease severity in rheumatoid arthritis. Proceedings of the National Academy of Sciences, 113(29), 8284–8289.

Labree, B., et al. (2025). Auricular ultrasonic vagus nerve stimulation: Effectiveness of low-intensity focused ultrasound.

Mayo Clinic. (2024). Vagus nerve stimulation. Mayo Clinic.

Peuker, E. T., & Filler, T. J. (2002). The nerve supply of the human auricle. Clinical Anatomy, 15(1), 35–37.

Wang, Y., Zhan, G., Cai, Z., Jiao, B., Zhao, Y., Li, S., & Luo, A. (2020). Transcutaneous auricular vagus nerve stimulation: From concept to application. Neuroscience Bulletin, 37, 853–862.

Yap, J. Y. Y., Keatch, C., Lambert, E., Woods, W., Stoddart, P. R., & Kameneva, T. (2020). Critical review of transcutaneous vagus nerve stimulation: Challenges for translation to clinical practice. Frontiers in Neuroscience, 14, 284.

Yuan, H., & Silberstein, S. D. (2016). Vagus nerve and vagus nerve stimulation, a comprehensive review: Part I. Headache, 56(1), 71–78. doi: 10.1111/head.12647. Epub 2015 Sep 14. PMID: 26364692.